XERIS PHARMATICALS ($XERS) posted quarterly earnings results for Q4 2025 on Monday, March 2nd. The company reported earnings of $0.06 per share, beating estimates of $0.04 by $0.02. The company also reported revenue of $85,810,000, beating estimates of $83,986,800 by $1,823,200.
You can see Quiver Quantitative's $XERS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
XERIS PHARMATICALS Insider Trading Activity
XERIS PHARMATICALS insiders have traded $XERS stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $XERS stock by insiders over the last 6 months:
- JOHN JOHNSON sold 135,400 shares for an estimated $977,019
- BETH HECHT (See Remarks) has made 0 purchases and 4 sales selling 66,668 shares for an estimated $487,999.
- JOHN PATRICK JR SHANNON (See Remarks) has made 0 purchases and 2 sales selling 48,149 shares for an estimated $349,658.
- KEVIN MCCULLOCH (See Remarks) sold 15,000 shares for an estimated $120,000
- MARLA PERSKY sold 15,500 shares for an estimated $119,610
- BARBARA-JEAN ANNE BORMANN-KENNEDY sold 15,000 shares for an estimated $106,414
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
XERIS PHARMATICALS Hedge Fund Activity
We have seen 109 institutional investors add shares of XERIS PHARMATICALS stock to their portfolio, and 141 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- D. E. SHAW & CO., INC. added 1,734,964 shares (+29.7%) to their portfolio in Q4 2025, for an estimated $13,619,467
- WELLINGTON MANAGEMENT GROUP LLP added 1,705,636 shares (+293.6%) to their portfolio in Q4 2025, for an estimated $13,389,242
- VANGUARD GROUP INC added 1,358,760 shares (+13.8%) to their portfolio in Q4 2025, for an estimated $10,666,266
- UBS GROUP AG removed 1,180,900 shares (-66.2%) from their portfolio in Q4 2025, for an estimated $9,270,065
- RENAISSANCE TECHNOLOGIES LLC removed 1,003,180 shares (-61.8%) from their portfolio in Q4 2025, for an estimated $7,874,963
- CUBIST SYSTEMATIC STRATEGIES, LLC removed 880,314 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $7,165,755
- BANK OF AMERICA CORP /DE/ removed 876,952 shares (-55.0%) from their portfolio in Q4 2025, for an estimated $6,884,073
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
XERIS PHARMATICALS Analyst Ratings
Wall Street analysts have issued reports on $XERS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Oppenheimer issued a "Outperform" rating on 10/29/2025
To track analyst ratings and price targets for XERIS PHARMATICALS, check out Quiver Quantitative's $XERS forecast page.
XERIS PHARMATICALS Price Targets
Multiple analysts have issued price targets for $XERS recently. We have seen 3 analysts offer price targets for $XERS in the last 6 months, with a median target of $10.0.
Here are some recent targets:
- Brandon Folkes from HC Wainwright & Co. set a target price of $10.0 on 01/09/2026
- Glen Santangelo from Barclays set a target price of $9.0 on 12/09/2025
- Leland Gershell from Oppenheimer set a target price of $18.0 on 10/29/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
